Convergence of miRNA expression profiling, α-synuclein interacton and GWAS in Parkinson's disease
…, BV Fonseca, K Gotovac, S Violante, T Mestre… - PloS one, 2011 - journals.plos.org
miRNAs were recently implicated in the pathogenesis of numerous diseases, including
neurological disorders such as Parkinson's disease (PD). miRNAs are abundant in the nervous …
neurological disorders such as Parkinson's disease (PD). miRNAs are abundant in the nervous …
Therapeutic interventions for symptomatic treatment in Huntington's disease
T Mestre, J Ferreira, MM Coelho… - Cochrane Database …, 2009 - cochranelibrary.com
Background Huntington's disease (HD) is an orphan autosomal dominant neurodegenerative
disorder caused by the amplification of a nucleic acids triplet repeat. It is characterised by …
disorder caused by the amplification of a nucleic acids triplet repeat. It is characterised by …
MDS evidence‐based review of treatments for essential tremor
JJ Ferreira, TA Mestre, KE Lyons… - Movement …, 2019 - Wiley Online Library
Background Essential tremor is one of the most prevalent movement disorders. Many
treatments for essential tremor have been reported in clinical practice, but it is uncertain which …
treatments for essential tremor have been reported in clinical practice, but it is uncertain which …
[HTML][HTML] Therapy of Parkinson's disease subtypes
C Marras, KR Chaudhuri, N Titova, TA Mestre - Neurotherapeutics, 2020 - Elsevier
Early descriptions of subtypes of Parkinson's disease (PD) are dominated by the approach of
predetermined groups. Experts defined, from clinical observation, groups based on clinical …
predetermined groups. Experts defined, from clinical observation, groups based on clinical …
A biological classification of Huntington's disease: the Integrated Staging System
…, B Borowsky, P Konstantinova, TA Mestre… - The Lancet …, 2022 - thelancet.com
The current research paradigm for Huntington's disease is based on participants with overt
clinical phenotypes and does not address its pathophysiology nor the biomarker changes …
clinical phenotypes and does not address its pathophysiology nor the biomarker changes …
Identification of genetic variants associated with Huntington's disease progression: a genome-wide association study
…, AM Descals, S Martinez-Horta, T Mestre… - The Lancet …, 2017 - thelancet.com
Background Huntington's disease is caused by a CAG repeat expansion in the huntingtin
gene, HTT. Age at onset has been used as a quantitative phenotype in genetic analysis …
gene, HTT. Age at onset has been used as a quantitative phenotype in genetic analysis …
A roadmap for implementation of patient‐centered digital outcome measures in Parkinson's disease obtained using mobile health technologies
…, SS Paul, FB Horak, JA Vizcarra, TA Mestre… - Movement …, 2019 - Wiley Online Library
Obtaining reliable longitudinal information about everyday functioning from individuals with
Parkinson's disease (PD) in natural environments is critical for clinical care and research. …
Parkinson's disease (PD) in natural environments is critical for clinical care and research. …
Global scales for cognitive screening in Parkinson's disease: Critique and recommendations
Background Cognitive impairment is a common nonmotor manifestation of Parkinson's disease,
with deficits ranging from mild cognitive difficulties in 1 or more of the cognitive domains …
with deficits ranging from mild cognitive difficulties in 1 or more of the cognitive domains …
Effect of urate-elevating inosine on early Parkinson disease progression: the SURE-PD3 randomized clinical trial
…, GM McMahon, L Pothier, SS Waikar, A Lang, T Mestre… - Jama, 2021 - jamanetwork.com
Importance Urate elevation, despite associations with crystallopathic, cardiovascular, and
metabolic disorders, has been pursued as a potential disease-modifying strategy for …
metabolic disorders, has been pursued as a potential disease-modifying strategy for …
Data analytics from Enroll‐HD, a global clinical research platform for Huntington's disease
…, F Cardoso, JJ Ferreira, TA Mestre… - Movement disorders …, 2017 - Wiley Online Library
Background The study of complex neurodegenerative diseases is moving away from
hypothesis‐driven biological methods toward large scale multimodal approaches, requiring …
hypothesis‐driven biological methods toward large scale multimodal approaches, requiring …